The Neothera Pre-Seed round of ₹9 crore, led by Blume Ventures, marks a significant early bet on science-driven consumer healthcare in India, as publicly reported on 2026-07-08. Neothera is a science-led skin health company that is reimagining how chronic skin conditions such as acne are diagnosed and treated. The round drew participation from institutional funds and a roster of high-profile angel investors, reflecting strong conviction in the startup’s category-defining ambition.
Quick Highlights
- Founder: Radhika Agarwal — former consumer-tech investor at Blume Ventures and Forbes 30 Under 30 Asia 2023 honouree
- Lead Investor: Blume Ventures
- Participating Investors: Barbershop Fund (the investment syndicate led by Bombay Shaving Company Founder Shantanu Deshpande), Consumer Collective, Veltis Capital, Arjun Purkayastha (SVP & Managing Director, Reckitt), Malika Sadani (Founder, The Moms Co.), Mukul Rastogi (Founder, Classplus), and Diksha Pandey (Founder, Samosa Party), among others
- Investor Background: Blume Ventures is one of India’s leading seed and pre-Series A funds, known for backing early-stage, tech-enabled consumer and enterprise ventures
- Headquarters: India
- Announcement Date: 8 July 2026
Funding Breakdown
Use of Funds
Neothera plans to deploy the ₹9 crore pre-seed capital across five priority areas: strengthening its technology platform, expanding its product portfolio, investing in research and development, building its clinical and scientific teams, and accelerating customer acquisition across India. The startup entered the market after nearly 20 months of research, product formulation, testing, and beta trials conducted alongside dermatologists, nutrition experts, and formulators — and the fresh capital will now accelerate that work at scale.
Funding Timeline
This ₹9 crore pre-seed round is Neothera’s first disclosed funding event. As publicly reported, the capital was originally secured in August 2025 at the idea stage, prior to any product launch — an unusually early point at which to attract institutional backing — and is now being formally announced as the company moves into active market operations.
Expansion Plans
Neothera’s near-term roadmap centres on scaling customer acquisition across India, growing its clinical and scientific teams, and broadening its product offerings beyond its inaugural 8-week acne care programme. The company combines root-cause diagnosis, personalised habit interventions, nutritional guidance, AI-powered support, and clinically tested formulations, and intends to deepen each of these capabilities with the new funding. As publicly reported, the startup aims to establish itself as a category-defining brand focused on long-term skin health rather than short-term skincare fixes.
Significance
Neothera’s Neothera Pre-Seed raise stands out because investors committed at the idea stage — before a single product reached consumers — a vote of confidence that is rare even in a buoyant Indian startup market. The deal also carries a compelling narrative: founder Radhika Agarwal spent nearly five years as a consumer-tech investor at Blume Ventures before making the leap to entrepreneurship, and Blume is now backing her own company, closing a full-circle journey. As Sajith Pai, Partner at Blume Ventures, noted publicly, “the skin health and derma-care market still remains underserved, despite being one of the largest opportunities in consumer healthcare.” By fusing diagnostics, behavioural science, nutrition, and clinically validated formulations into a single integrated model, Neothera is staking a claim in a segment that consumer brands have largely ignored in favour of topical, symptom-focused products — making this round a signal that outcome-driven skin health may be India’s next major consumer healthcare category.
These details have been verified against multiple publicly available reports as of 2026-07-08.
Stay updated with the latest startup funding news on The Courtroom.
Disclaimer: This report is compiled from publicly available sources and is for informational purposes only; funding figures are as publicly reported and may be subject to change.
